Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Stereotactic Body Radiation Therapy
100%
Dose-escalation Study
100%
Resectable Pancreatic Cancer
100%
Distant Metastasis
33%
Gastrointestinal Toxicity
33%
Dose-limiting Toxicity
33%
Local Failure
33%
Distant Progression
33%
In(III)
16%
Quality of Life
16%
Cumulative Incidence
16%
Confidence Interval
16%
Consecutive Patients
16%
Dose Escalation
16%
Overall Survival
16%
Systemic Therapy
16%
Chemotherapy
16%
Cancer Treatment
16%
Disease Outcome
16%
Quality of Life Assessment
16%
Dose Level
16%
Tumor Location
16%
Tumor Size
16%
Induction Chemotherapy
16%
Progression-free Survival
16%
Quality of Life Questionnaire
16%
Quality of Life Outcomes
16%
Single Fraction
16%
Tumor Control
16%
Maximum Tolerated Dose
16%
Optimal Dose
16%
Median Range
16%
Memorial Sloan-Kettering Cancer Center
16%
European Organizations
16%
Dose-escalation Trial
16%
Uncinate
16%
3 + 3 Design
16%
University of Colorado
16%
Efficient Integration
16%
Carbohydrate Antigen 19-9 (CA19-9)
16%
National Cancer Institute Common Terminology Criteria for Adverse Events
16%
Optimal Fractionation
16%
Medicine and Dentistry
Stereotactic Body Radiation Therapy
100%
Pancreas Cancer
100%
Quality of Life
50%
Neoplasm
50%
Malignant Neoplasm
33%
Distant Metastasis
33%
Gastrointestinal Toxicity
33%
Adverse Event
16%
Cumulative Incidence
16%
Progression Free Survival
16%
Overall Survival
16%
Induction Chemotherapy
16%
Cancer Treatment
16%
Systemic Therapy
16%
Optimal Drug Dose
16%
Quality of Life Assessment
16%
CA19-9
16%
Diseases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
Malignant Neoplasm
60%
Neoplasm
60%
Chemotherapy
40%
Distant Metastasis
40%
Gastrointestinal Toxicity
40%
Adverse Event
20%
Overall Survival
20%
Progression Free Survival
20%
Maximum Tolerated Dose
20%
Diseases
20%